ALPN News and Press, Alpine Immune Sciences Inc. From 04/25/20

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced the company will present a poster at the AACR Virtual Annual Meeting I, taking place April...

Alpine Immune Sciences, Inc. (ALPN) Q4 2019 Earnings Conference Call March 30, 2020 16:30 ET Company Participants Courtney Dugan - Investor Relations Mitchell Gold - Chairman and Chief Executive Officer Stanford Peng - President and Head, Research and Development Paul Rickey - ...

Alpine Immune Sciences (NASDAQ: ALPN ): Q4 GAAP EPS of -$0.33 beats by $0.25 . More news on: Alpine Immune Sciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Completion of Phase 1 Study for Lead Autoimmune/Inflammatory Disease Program, ALPN-101 BALANCE Trial of ALPN-101 in Acute GVHD Open for Enrollment NEON-1 Trial of ALPN-202 in Advanced Malignancies Open for Enrollment Orphan Drug Designations by the U.S. FDA for ALPN-101 ...

Thinly traded nano cap Alpine Immune Sciences ( ALPN   +7% ) is up out of the gate this morning on the heels of two U.S. Orphan Drug indications for lead candide ALPN-101, a dual T cell costimulation inhibitor. More news on: Alpine Immune Sciences, Inc., Healthcare stocks news, Stoc...

Company to Hold Conference Call to Discuss Fourth Quarter and Full Year 2019 Results on March 30, 2020 Alpine Immune Sciences, Inc. (NASDAQ:ALPN) , a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases...

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing treatments for autoimmune/inflammatory diseases and cancer, today announced the company will present at two upcoming investor healthcare conferences in March. Cowen 40 th Annual Healthcare ...

Gilead Tests Potential Ebola Treatment for Coronavirus Gilead Sciences ( GILD ) announced that it is currently in the process of evaluating the use of its experimental Ebola candidate, Nuc inhibitor GS-5734, for treating 2019-nCov infection. The company is currently engaged in active discu...

Thinly traded nano cap Alpine Immune Sciences (NASDAQ: ALPN ) is up  8%  premarket, albeit on only 1,008 shares, on the heels of new preclinical data on lead candidate ALPN-101. The results were presented at the Crohn's & Colitis Congress in Austin, TX. More news on: Alpine...